Abstract
THE INTRATHECAL USE of methylprednisolone acetate in the treatment of sciatica and arachnitis was introduced in 1961 by Gardner and associates. 1 In reporting 3 1/2 years of experience with the intrathecal use of methylprednisolone acetate, Sehgal and Gardner 2 noted the complete absence of serious complications. More recently, Shealy 3 described the case of a patient with sciatic pain, treated with methylprednisolone acetate given intrathecally, in whom Cryptococcus neoformans meningitis later developed. He emphasized the need for careful evaluation of patients before the intrathecal use of drugs. During the past 14 months, 53 patients on the neurosurgical service have been treated with methylprednisolone acetate given intrathecally for low back and lower-extremity pain after myelography. Tuberculous meningitis subsequently developed in one of the patients. The relationship between the use of systemic steroids and the development and dissemination of pulmonary tuberculosis has been known for some time. The appearance of tuberculous
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
